Verona Pharma plc: Grant of Options to PDMR

LONDON, Nov. 27, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that, on November 26, 2019, it granted 500,000 options to purchase ordinary shares of £0.05 each (the “Ordinary Shares”) to its CEO, Dr. Jan-Anders Karlsson, under and in accordance with Verona Pharma’s 2017 Incentive Award Plan (which is set out in Verona Pharma’s 2018 annual report and 20-F) (the “Options”).
The Options have an exercise price of £0.445 per Ordinary Share, being the closing mid-market price on November 25, 2019. The Options will vest over two different periods following the grant date:  250,000 of the options will vest in three substantially equal annual instalments and the other half of the Options will vest in four substantially equal annual instalments.Further information is provided below in accordance with the requirements of the EU Market Abuse Regulation.For further information, please contact:Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.